https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Passage_Bio%2C_Inc. 2026-05-09T06:39:47Z Istoricul versiunilor pentru această pagină din wiki MediaWiki 1.39.2 https://wiki.tradeville.ro/index.php?title=Passage_Bio,_Inc.&diff=530263&oldid=prev 2024-11-27T16:10:47Z

<p>The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ro"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Versiunea anterioară</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Versiunea de la data 27 noiembrie 2024 19:10</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Linia 1:</td> <td colspan="2" class="diff-lineno">Linia 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Pagina dedicata companiei Passage Bio, Inc. listata cu simbolul US.PASG</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Pagina dedicata companiei Passage <ins style="font-weight: bold; text-decoration: none;">[[BIO|</ins>Bio<ins style="font-weight: bold; text-decoration: none;">]]</ins>, Inc. listata cu simbolul US.PASG</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td></tr> <!-- diff cache key tradeville_wiki:diff::1.12:old-448885:rev-530263 --> </table>

127.0.0.1 https://wiki.tradeville.ro/index.php?title=Passage_Bio,_Inc.&diff=448885&oldid=prev 2024-10-02T15:55:39Z

<p>The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ro"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Versiunea anterioară</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Versiunea de la data 2 octombrie 2024 18:55</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Linia 2:</td> <td colspan="2" class="diff-lineno">Linia 2:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Passage Bio, Inc. is (https://www.passagebio.com/) a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Passage Bio, Inc. is (https://www.passagebio.com/) a clinical-stage genetic medicines company. It is focused on developing transformative therapies for <ins style="font-weight: bold; text-decoration: none;">[[CENTRAL|</ins>central<ins style="font-weight: bold; text-decoration: none;">]] </ins>nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td></tr> <!-- diff cache key tradeville_wiki:diff::1.12:old-434937:rev-448885 --> </table>

127.0.0.1 https://wiki.tradeville.ro/index.php?title=Passage_Bio,_Inc.&diff=434937&oldid=prev 2024-09-18T18:20:07Z

<p>Pagină nouă: Pagina dedicata companiei Passage Bio, Inc. listata cu simbolul US.PASG ==Descriere companie== Passage Bio, Inc. is (https://www.passagebio.com/) a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for ganglios...</p> <p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Passage Bio, Inc. listata cu simbolul US.PASG<br /> <br /> ==Descriere companie==<br /> Passage Bio, Inc. is (https://www.passagebio.com/) a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.<br /> <br /> ==Grafic actiuni companie==<br /> &lt;iframe key=&quot;tradeville&quot; path=&quot;graficSimbol/US.PASG&quot; /&gt;<br /> <br /> ==Ultimele stiri despre Passage Bio, Inc. (US.PASG)==<br /> &lt;dynamicpagelist&gt;<br /> category=US.PASG<br /> count=10<br /> order=descending<br /> addfirstcategorydate=false<br /> &lt;/dynamicpagelist&gt;<br /> <br /> [[Categorie:US.PASG]][[Categorie:Stiri despre companii]]</div>

Admin